菜单
Recommends that medical therapy for acromegaly be withheld during pregnancy and administered only for tumor control and headache relief. Consider when managing a pregnant patient with acromegaly who presents with tumor growth or worsening headache.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
基于 SOC 职业分类
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-withhold-medical-therapy-pregnancy-except-tumor-headache命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
正在显示 SKILL.md
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
| name | endo-withhold-medical-therapy-pregnancy-except-tumor-headache |
| description | Recommends that medical therapy for acromegaly be withheld during pregnancy and administered only for tumor control and headache relief. Consider when managing a pregnant patient with acromegaly who presents with tumor growth or worsening headache. |
Confirm pregnancy status (gestational age, symptoms). Review current acromegaly therapy (long-acting SRL, pegvisomant, cabergoline). Assess for headache frequency/severity and tumor-related symptoms (visual changes, bitemporal hemianopsia, new neurologic deficits). Perform or review recent visual field testing and pituitary MRI if available. Document baseline IGF-1 and GH only if clinically indicated for non‑pregnancy-related concerns (otherwise avoid routine pregnancy monitoring).
Is there evidence of tumor growth (progressive visual field defect, new neurologic symptoms, or radiographic progression) or uncontrolled headache requiring intervention?
Classify headache as mild (intermittent, responsive to acetaminophen) or moderate‑severe (daily, disabling). Assess tumor status as stable (no change in visual fields/MRI) or progressive (worsening visual fields, radiographic growth).
Withhold long‑acting SRLs (lanreotide autogel/depot, octreotide LAR) and pegvisomant throughout pregnancy. For tumor control or headache relief, administer short‑acting octreotide (50‑100 µg SC) every 6‑8 hours as needed, titrating to symptom relief. Discontinue short‑acting octreotide once symptoms resolve. Schedule visual field testing every trimester and clinical assessment monthly; resume pre‑pregnancy medical therapy postpartum after lactation cessation if desired.
Do not initiate or continue long‑acting SRLs, pegvisomant, or long‑acting cabergoline during pregnancy due to limited fetal safety data. Avoid routine GH/IGF‑1 monitoring in pregnancy as placental GH confounds assays. Do not assume cabergoline is safe without obstetric consultation; use only if prolactinoma co‑exists and under specialist guidance. Monitor for gestational diabetes and hypertension, which are modestly increased in acromegaly. Never withhold therapy for acute visual field deterioration; treat promptly with short‑acting octreotide and neurosurgical evaluation.
A 28‑year‑on woman with acromegaly on lanreotide autogel 120 mg monthly presents at 14 weeks gestation with worsening frontotemporal headache; visual fields are stable and MRI shows no tumor change. Discontinue lanreotide, treat headache with short‑acting octreotide 50 µg SC q6‑8 h PRN, and reassess headache daily. Headache resolves by week 16; octreotide is tapered off. Continue obstetric follow‑up and plan to restart lanreotide postpartum.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700